Skip to main content
Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.613
+0.006 (0.91%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Vistagen Therapeutics Revenue

Vistagen Therapeutics had revenue of $303.00K in the quarter ending December 31, 2025, with 29.49% growth. This brings the company's revenue in the last twelve months to $789.00K, up 13.04% year-over-year. In the fiscal year ending March 31, 2025, Vistagen Therapeutics had annual revenue of $486.00K, down -54.32%.

Revenue (ttm)
$789.00K
Revenue Growth
+13.04%
P/S Ratio
30.52
Revenue / Employee
$13,373
Employees
59
Market Cap
24.27M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 2025486.00K-578.00K-54.32%
Mar 31, 20241.06M1.29M-568.72%
Mar 31, 2023-227.00K-1.34M-120.47%
Mar 31, 20221.11M19.40K1.78%
Mar 31, 20211.09M--
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro
Mar 31, 2018 Pro Pro Pro
Mar 31, 2017 Pro Pro Pro
Mar 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Neuphoria Therapeutics 14.99M
Barinthus Biotherapeutics 14.97M
Marker Therapeutics 4.69M
Exicure 500.00K
Hyperion DeFi 345.32K
Daré Bioscience -57.13K
Revenue Rankings

VTGN News

More News